Tags

Type your tag names separated by a space and hit enter

Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease.
Alzheimers Res Ther. 2015; 7(1):51.AR

Abstract

INTRODUCTION

Circulating levels of uridine, selenium, vitamins B12, E and C, folate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been shown to be lower in patients with Alzheimer's disease (AD) than in healthy individuals. These low levels may affect disease pathways involved in synapse formation and neural functioning. Here, we investigated whether, and to what extent, circulating levels of micronutrients and fatty acids can be affected by oral supplementation with Souvenaid (containing a specific nutrient combination), using data derived from three randomized clinical trials (RCT) and an open-label extension (OLE) study with follow-up data from 12 to 48 weeks.

METHODS

Subjects with mild (RCT1, RCT2) or mild-to-moderate AD (RCT3) received active or control product once daily for 12-24 weeks or active product during the 24-week OLE following RCT2 (n = 212-527). Measurements included plasma levels of B vitamins, choline, vitamin E, selenium, uridine and homocysteine and proportions of DHA, EPA and total n-3 long-chain polyunsaturated fatty acids in plasma and erythrocytes. Between-group comparisons were made using t tests or non-parametric alternatives.

RESULTS

We found that 12-24-week active product intake increased plasma and/or erythrocyte micronutrients: uridine; choline; selenium; folate; vitamins B6, B12 and E; and fatty acid levels of DHA and EPA (all p < 0.001). In the OLE study, similar levels were reached in former control product/initial active product users, whereas 24-week continued active product intake showed no suggestion of a further increase in nutrient levels.

CONCLUSIONS

These data show that circulating levels of nutrients known to be decreased in the AD population can be increased in patients with mild and mild-tomoderate AD by 24-48-week oral supplementation with Souvenaid. In addition, to our knowledge, this is the first report of the effects of sustained dietary intake of uridine monophosphate on plasma uridine levels in humans. Uptake of nutrients is observed within 6 weeks, and a plateau phase is reached for most nutrients during prolonged intake, thus increasing the availability of precursors and cofactors in the circulation that may be used for the formation and function of neuronal membranes and synapses in the brain.

Links

PMC Free PDF

Authors+Show Affiliations

Rijpma A
Radboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
Meulenbroek O
Radboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.
van Hees AM
Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
Sijben JW
Nutricia Research, Nutricia Advanced Medical Nutrition, Utrecht, The Netherlands.
Vellas B
Gerontopole, INSERM U1027, Toulouse, France.
Shah RC
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL USA.
Bennett DA
Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL USA.
Scheltens P
Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands.
Olde Rikkert MG
Radboud Alzheimer Center, Department of Geriatric Medicine, Radboud University Medical Center, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands.

MeSH

AgedAlzheimer DiseaseDietary SupplementsDouble-Blind MethodFatty AcidsFemaleFood, FormulatedHumansInflammationMaleMicronutrientsNeuroprotective AgentsOxidative StressSeverity of Illness IndexTreatment Outcome

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26213579

Citation

Rijpma, Anne, et al. "Effects of Souvenaid On Plasma Micronutrient Levels and Fatty Acid Profiles in Mild and Mild-to-moderate Alzheimer's Disease." Alzheimer's Research & Therapy, vol. 7, no. 1, 2015, p. 51.
Rijpma A, Meulenbroek O, van Hees AM, et al. Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. Alzheimers Res Ther. 2015;7(1):51.
Rijpma, A., Meulenbroek, O., van Hees, A. M., Sijben, J. W., Vellas, B., Shah, R. C., Bennett, D. A., Scheltens, P., & Olde Rikkert, M. G. (2015). Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. Alzheimer's Research & Therapy, 7(1), 51. https://doi.org/10.1186/s13195-015-0134-1
Rijpma A, et al. Effects of Souvenaid On Plasma Micronutrient Levels and Fatty Acid Profiles in Mild and Mild-to-moderate Alzheimer's Disease. Alzheimers Res Ther. 2015;7(1):51. PubMed PMID: 26213579.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of Souvenaid on plasma micronutrient levels and fatty acid profiles in mild and mild-to-moderate Alzheimer's disease. AU - Rijpma,Anne, AU - Meulenbroek,Olga, AU - van Hees,Anneke M J, AU - Sijben,John W C, AU - Vellas,Bruno, AU - Shah,Raj C, AU - Bennett,David A, AU - Scheltens,Philip, AU - Olde Rikkert,Marcel G M, Y1 - 2015/07/24/ PY - 2014/12/30/received PY - 2015/06/16/accepted PY - 2015/7/28/entrez PY - 2015/7/28/pubmed PY - 2016/5/4/medline SP - 51 EP - 51 JF - Alzheimer's research & therapy JO - Alzheimers Res Ther VL - 7 IS - 1 N2 - INTRODUCTION: Circulating levels of uridine, selenium, vitamins B12, E and C, folate, docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) have been shown to be lower in patients with Alzheimer's disease (AD) than in healthy individuals. These low levels may affect disease pathways involved in synapse formation and neural functioning. Here, we investigated whether, and to what extent, circulating levels of micronutrients and fatty acids can be affected by oral supplementation with Souvenaid (containing a specific nutrient combination), using data derived from three randomized clinical trials (RCT) and an open-label extension (OLE) study with follow-up data from 12 to 48 weeks. METHODS: Subjects with mild (RCT1, RCT2) or mild-to-moderate AD (RCT3) received active or control product once daily for 12-24 weeks or active product during the 24-week OLE following RCT2 (n = 212-527). Measurements included plasma levels of B vitamins, choline, vitamin E, selenium, uridine and homocysteine and proportions of DHA, EPA and total n-3 long-chain polyunsaturated fatty acids in plasma and erythrocytes. Between-group comparisons were made using t tests or non-parametric alternatives. RESULTS: We found that 12-24-week active product intake increased plasma and/or erythrocyte micronutrients: uridine; choline; selenium; folate; vitamins B6, B12 and E; and fatty acid levels of DHA and EPA (all p < 0.001). In the OLE study, similar levels were reached in former control product/initial active product users, whereas 24-week continued active product intake showed no suggestion of a further increase in nutrient levels. CONCLUSIONS: These data show that circulating levels of nutrients known to be decreased in the AD population can be increased in patients with mild and mild-tomoderate AD by 24-48-week oral supplementation with Souvenaid. In addition, to our knowledge, this is the first report of the effects of sustained dietary intake of uridine monophosphate on plasma uridine levels in humans. Uptake of nutrients is observed within 6 weeks, and a plateau phase is reached for most nutrients during prolonged intake, thus increasing the availability of precursors and cofactors in the circulation that may be used for the formation and function of neuronal membranes and synapses in the brain. SN - 1758-9193 UR - https://www.unboundmedicine.com/medline/citation/26213579/Effects_of_Souvenaid_on_plasma_micronutrient_levels_and_fatty_acid_profiles_in_mild_and_mild_to_moderate_Alzheimer's_disease_ DB - PRIME DP - Unbound Medicine ER -